Prostate cancer, Secondary cancers
Results
Phase 3
This trial compared a drug called rucaparib with for prostate cancer.
It was for men with:
prostate cancer that had spread and got worse despite having hormone treatment. This is called metastatic castration resistant prostate cancer (mCRPC).
certain gene changes () in the prostate cancer cells
The trial was open for people to join between 2017 and 2022. The team published the results in 2023.
Recruitment start: 21 June 2017
Recruitment end: 3 February 2022
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Elias Pintus
Clovis Oncology, Inc
Last reviewed: 25 July 2024
CRUK internal database number: 14734
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
